Drug Type Small molecule drug |
Synonyms Mizoribine (JP17/INN), HE-69, NSC-289637 + [3] |
Target |
Mechanism IMPDH inhibitors(Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (15 Feb 1984), |
RegulationOrphan Drug (US) |
Molecular FormulaC9H13N3O6 |
InChIKeyHZQDCMWJEBCWBR-UUOKFMHZSA-N |
CAS Registry50924-49-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01392 | Mizoribine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Nephrotic Syndrome | JP | 29 Sep 1995 | |
Rheumatoid Arthritis | JP | 02 Oct 1992 | |
Lupus Nephritis | JP | 28 Sep 1990 | |
Renal transplant rejection | JP | 15 Feb 1984 |
Not Applicable | 84 | Previous combination therapy (PSL and MZB) | mejjewqpmc(qzsdkyaiwn) = obwusdnnjf yrbsgswkip (lmkhkbeayj ) View more | Positive | 27 Oct 2021 | ||
New combination therapy (PSL, MZB, and lisinopril) | mejjewqpmc(qzsdkyaiwn) = ymogpsduki yrbsgswkip (lmkhkbeayj ) View more | ||||||
Not Applicable | Glomerulonephritis, IGA CD163 + | CD300e | 73 | Prednisolone (PSL) plus Mizoribine (Miz) | nhjvemfpty(vofvccsbuy) = the number of interstitial CD163 + MQ were significantly reduced in the PM group, but not in the P group rnlsdovfvx (gjaipvhwfg ) View more | Positive | 05 Nov 2019 | |
Not Applicable | Idiopathic Membranous Glomerulonephritis anti-phospholipase A2 receptor antibody (PLA2R-Ab) | - | Mizoribine 150 mg + Prednisolone 30 mg | nagykzcuwb(kvbhykqmgl) = zcvpqtzdbd ynnlazytlp (nnsqgqvcmi ) | Positive | 13 Jun 2019 | |
nagykzcuwb(kvbhykqmgl) = ngsejvdfcy ynnlazytlp (nnsqgqvcmi ) | |||||||
Not Applicable | - | - | Mizoribine, Tacrolimus, Corticosteroids | srpyqdswux(vaqnwlblrn) = bvkjdsnage ckjujrxjwd (eevkimuodi ) View more | - | 01 Jun 2019 | |
Mycophenolate mofetil, Tacrolimus, Corticosteroids | srpyqdswux(vaqnwlblrn) = dadmenmvlj ckjujrxjwd (eevkimuodi ) View more | ||||||
Not Applicable | Idiopathic Membranous Glomerulonephritis anti-phospholipase A2 receptor antibody (PLA2R-Ab) | - | Mizoribine 150 mg + Prednisolone 30 mg | aeysnwcjrt(sjrlcptaqb) = fihzmlbngx czvnpjszre (xpykkkuunf ) | Positive | 31 Oct 2017 | |
Not Applicable | 47 | Mizoribine, Tacrolimus, and Prednisolone | aefbyxmrcd(ghmijpdfju) = 14 cases had some Infection, 3 out of 14 needed antibiotics treatment xqhtcuqyiy (cfqbnqynfr ) View more | Positive | 14 Jun 2017 | ||
Not Applicable | Idiopathic Membranous Glomerulonephritis anti-phospholipase A2 receptor (PLA2R) | - | Mizoribine 150 mg + Prednisolone 30 mg | pudbmajqqp(yrtjtitvtn) = vbuyzvplwx uedlpzpkhv (wkzkbnqovz ) View more | Positive | 26 May 2017 | |
pudbmajqqp(yrtjtitvtn) = gpffwqiwgv uedlpzpkhv (wkzkbnqovz ) View more | |||||||
Not Applicable | 24 | jpmwgfyxtx(nkznfacgii) = 1 patient developed gastrointestinal symptom in MTX group, and 1 patient developed gastrointestinal symptom in MZR group emweiyryhd (sihwfrwmfh ) View more | Positive | 08 Jun 2016 | |||
Not Applicable | 576 | mtmqblixek(vkfpaiuycv) = Adverse reactions occurred in 60 of the 443 subjects (13.5%). The main adverse reactions were 12 events (2.7%) of herpes zoster, 5 events (1.1%) of hyperuricemia, and 4 events (0.9%) of anemia. Serious adverse drug reactions were observed in 12 patients (2.7%) ghlmqknciz (nhalcyvysm ) | Positive | 10 Jun 2015 | |||
Not Applicable | - | hbyeqjnqed(xrfjclfcdc) = bbqmdwuzav fgmqalisqj (ghxhmgnnme ) View more | Negative | 11 Nov 2014 | |||
Mizoribine (150 mg/day for 2 years) in combination with pulse methylprednisolone followed by 2-year course of oral prednisolone | hbyeqjnqed(xrfjclfcdc) = wcohmdrsey fgmqalisqj (ghxhmgnnme ) View more |